1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Predictive Technology Group, Inc.

Predictive Technology Group, Inc.

PRED
Predictive Technology Group, Inc.US flagOther OTC
0.00
USD
- -
- -
89,879.00Market Cap
2006 Y
2007 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.07
0.16
0.08
0.06
Basic EPS, GAAP
-0.08
-0.15
-0.1
-0.03
-0.03
-0.06
-0.3
-0.23
Free Cash Flow per Basic Share
-0.06
-0.05
- -
- -
-0.01
- -
-0.05
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.04
-0.18
-0.1
-0.11
-0.11
-0.15
-0.44
-0.52
Tangible Book Value per Share
0.11
-0.03
0.1
0.1
0.16
0.14
-0.01
-0.05
Basic Weighted Avg Shares
- -
- -
164
202
241
266
290
300
Sales/Revenue/Turnover
- -
- -
- -
3
17
43
24
19
Operating Margin (%)
- -
- -
-3,171.94
-185.22
-74.14
-45.85
-190.92
-135.36
Depreciation Expense
- -
- -
1
4
5
9
11
9
Net Income, GAAP
- -
- -
-17
-6
-6
-15
-86
-68
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-22,059.05
-238.78
-36.5
-35.19
-350.92
-355.44
Working Capital
- -
- -
- -
- -
-1
-5
-13
-22
LT Debt
- -
- -
- -
- -
- -
2
6
3
Total Equity
- -
- -
40
42
81
113
55
32
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'21
Dec'21
Mar'21
ST Debt
3
8
10
LT Borrowings
7
2
3
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
300
300
300
Market Capitalization
44
18
48

Working Capital

FRC

•

in mil. unless spec.
Sep'21
Dec'21
Mar'21
Total Current Assets
8
6
9
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
1
- -
2
Inventories
1
1
1
Total Current Liabilities
23
29
31
Payables & Accruals
14
15
14
ST Debt
3
8
10
Deferred Revenue
5
6
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-146,960.4%
-51.2%
Free Cash Flow
- -
-294.5%
-1,892.34%
Net Income, GAAP
- -
11,805.57%
460.39%
Sales/Revenue/Turnover
- -
- -
-43.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
8
11
11
13
43
2020
8
7
6
3
24
2021
5
4
7
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.01
-0.01
-0.01
- -
-0.06
2020
-0.03
-0.09
-0.05
- -
-0.3
2021
-0.05
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Bradley C. Robinson
Full Time Employees
62
Sector
Healthcare
Industry
Biotechnology
Address
2735 Parleys Way Salt Lake City UT United States of America 84109
IPO Date
Jan 2, 2008
CIK
0001382943
Website
predtechgroup.com
Similar Companies
Hugel, Inc. (145020.KQ)
Ceryvyn Therapeutics Ltd (CYV.AX)
Serina Therapeutics, Inc. (SER)
Baudax Bio, Inc. (BXRX)
Photocure ASA (0IMT.L)
Carmell Therapeutics Corporation (CTCXW)
Business
Predictive Technology Group, Inc. (PREDQ) develops and commercializes novel molecular diagnostics, therapeutics, and human cellular and tissue-based products (HCT/Ps) for personalized medicine in the biotechnology and life sciences sectors; its core offerings include FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women with infertility linked to endometriosis and related conditions; and regenerative medicine products such as AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for tissue repair and regenerative applications. The company operates through two primary segments, Human Cellular and Tissue Products (HCT/Ps) and Diagnostics and Therapeutics, with a focus on data analytics-driven disease identification, genomic mapping, and companion diagnostics via subsidiaries including Predictive Analytics, Predictive Laboratories, and Predictive Biotech; it maintains a collaboration with Atrin Pharmaceuticals LLC to advance molecular tools for cancer patient selection. Founded in 2005 and headquartered in Salt Lake City, Utah, Predictive Technology Group, Inc., formerly Global Enterprises Group, Inc., which changed its name in July 2015, primarily serves clinicians, patients, and healthcare providers in the U.S. focused on women's health, fertility, and regenerative therapies. In November 2023, the company filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the District of Utah, which converted to Chapter 7 liquidation on January 12, 2024.